This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Doramectin
Accession Number
DB11400
Type
Small Molecule
Groups
Vet approved
Description

Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle.

Structure
Thumb
Synonyms
Not Available
External IDs
L 701023 / L-701023 / UK 67994 / UK-67,994 / UK-67994
Categories
UNII
KGD7A54H5P
CAS number
Not Available
Weight
Average: 899.128
Monoisotopic: 898.507857063
Chemical Formula
C50H74O14
InChI Key
QLFZZSKTJWDQOS-YDBLARSUSA-N
InChI
InChI=1S/C50H74O14/c1-27-13-12-16-34-26-57-47-42(51)30(4)21-37(50(34,47)54)48(53)60-36-22-35(63-49(25-36)20-19-29(3)45(64-49)33-14-10-9-11-15-33)18-17-28(2)44(27)61-41-24-39(56-8)46(32(6)59-41)62-40-23-38(55-7)43(52)31(5)58-40/h12-13,16-17,19-21,27,29,31-33,35-47,51-52,54H,9-11,14-15,18,22-26H2,1-8H3/b13-12+,28-17+,34-16+/t27-,29-,31-,32-,35+,36-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47+,49+,50+/m0/s1
IUPAC Name
(1'R,2S,4'S,5S,6R,8'R,10'E,12'S,13'S,14'E,20'R,21'R,24'S)-6-cyclohexyl-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-5,6-dihydro-3',7',19'-trioxaspiro[pyran-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one
SMILES
[H]\C1=C(C)/[C@@]([H])(O[C@@]2([H])C[C@]([H])(OC)[C@@]([H])(O[C@@]3([H])C[C@]([H])(OC)[C@@]([H])(O)[C@]([H])(C)O3)[C@]([H])(C)O2)[C@@]([H])(C)\C([H])=C(/[H])\C(\[H])=C2/CO[C@]3([H])[C@]([H])(O)C(C)=C[C@@]([H])(C(=O)O[C@@]4([H])C[C@@]([H])(C1)O[C@@]1(C4)O[C@]([H])(C4CCCCC4)[C@@]([H])(C)C=C1)[C@]23O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Doramectin.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Doramectin.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Doramectin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthineDoramectin may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Doramectin.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Doramectin.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Doramectin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Doramectin.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Doramectin.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Doramectin is combined with 5-methoxy-N,N-dimethyltryptamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Doramectin--a novel avermectin. Vet Parasitol. 1993 Jul;49(1):1-119. [PubMed:8236732]
  2. Goudie AC, Evans NA, Gration KA, Bishop BF, Gibson SP, Holdom KS, Kaye B, Wicks SR, Lewis D, Weatherley AJ, et al.: Doramectin--a potent novel endectocide. Vet Parasitol. 1993 Jul;49(1):5-15. [PubMed:8236738]
  3. Yas-Natan E, Shamir M, Kleinbart S, Aroch I: Doramectin toxicity in a collie. Vet Rec. 2003 Dec 6;153(23):718-20. [PubMed:14690080]
  4. Stewart TB, Fox MC, Wiles SE: Doramectin efficacy against gastrointestinal nematodes in pigs. Vet Parasitol. 1996 Nov 1;66(1-2):101-8. [PubMed:8988561]
  5. Escudero E, Carceles CM, Diaz MS, Sutra JF, Galtier P, Alvinerie M: Pharmacokinetics of moxidectin and doramectin in goats. Res Vet Sci. 1999 Oct;67(2):177-81. [PubMed:10502489]
  6. Li N, Jiang H, Li J, Wang Z, Li C, Li X, Ding S: Pharmacokinetics of doramectin in rabbits after subcutaneous administration. J Vet Pharmacol Ther. 2009 Aug;32(4):397-9. doi: 10.1111/j.1365-2885.2008.01044.x. [PubMed:19614846]
  7. Atta AH, Abo-Shihada MN: Comparative pharmacokinetics of doramectin and ivermectin in sheep. J Vet Pharmacol Ther. 2000 Feb;23(1):49-52. [PubMed:10747243]
  8. Yazwinski TA, Tucker C, Featherston H, Johnson Z, Wood-Huels N: Endectocidal efficacies of doramectin in naturally parasitized pigs. Vet Parasitol. 1997 Jun;70(1-3):123-8. [PubMed:9195716]
  9. Ranjan S, Trudeau C, Prichard RK, Daigneault J, Rew RS: Nematode reinfection following treatment of cattle with doramectin and ivermectin. Vet Parasitol. 1997 Sep;72(1):25-31. [PubMed:9403974]
  10. Nentwig A, Oevermann A, Burgener IA: [Doramectin intoxication in 3 kittens]. Schweiz Arch Tierheilkd. 2014 Apr;156(4):179-83. doi: 10.1024/0036-7281/a000573. [PubMed:24686818]
External Links
ChemSpider
8008478
ChEMBL
CHEMBL2361641
Wikipedia
Doramectin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00599 mg/mLALOGPS
logP4.31ALOGPS
logP6.27ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)12.47ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area170.06 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity238.58 m3·mol-1ChemAxon
Polarizability99.09 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Not Available
Direct Parent
Macrolides and analogues
Alternative Parents
Disaccharides / O-glycosyl compounds / Ketals / Oxanes / Pyrans / Tertiary alcohols / Tetrahydrofurans / Secondary alcohols / Lactones / Carboxylic acid esters
show 6 more
Substituents
Macrolide / Disaccharide / Glycosyl compound / O-glycosyl compound / Ketal / Oxane / Pyran / Tetrahydrofuran / Tertiary alcohol / Secondary alcohol
show 16 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. [PubMed:11020135]

Drug created on February 25, 2016 11:25 / Updated on September 02, 2019 19:23